Názor k článku Očkování a autismus ve světle nového vědeckého objevu od Autor - Protiargumentovat tím, na čem se strany shodou. To...

Protiargumentovat tím, na čem se strany shodou. To je věru již kumštýřské!

Ale abych zůstal věcný. Nyní nikoliv pro zástupce Avenieru, ale pro uvažující čtenáře této diskuse: Pan TSD má na mysli především tuto pětiletou observační studii:

Eff ectiveness of maternal pertussis vaccination in England:
an observational study/ Gayatri Amirthalingam, Nick Andrews, Helen Campbell, Sonia Ribeiro, Edna Kara, Katherine Donegan, Norman K Fry, Elizabeth Miller, Mary Ramsay

Pokud však věnujete pozornost metodice této studie a tomu co říká ve světle toho, co především vůbec neříká, je zjevné, že nemůže být interpretována jako důkaz bezpečnosti očkování v těhotenství pro plod s ohledem na vývojová rizika autismu a schizofrenie:

Methods We undertook an analysis of laboratory-confi rmed cases and hospital admissions for pertussis in infants
between Jan 1, 2008, and Sept 30, 2013, using data submitted to Public Health England as part of its enhanced
surveillance of pertussis in England, to investigate the eff ect of the vaccination programme. We calculated vaccine
eff ectiveness by comparing vaccination status for mothers in confi rmed cases with estimates of vaccine coverage for
the national population of pregnant women, based on data from the Clinical Practice Research Datalink.

Findings The monthly total of confi rmed cases peaked in October, 2012 (1565 cases), and subsequently fell across all
age groups. For the fi rst 9 months of 2013 compared with the same period in 2012, the greatest proportionate fall in
confi rmed cases (328 cases in 2012 vs 72 cases in 2013, –78%, 95% CI –72 to –83) and in hospitalisation admissions
(440 admissions in 2012 vs 140 admissions in 2013, –68%, –61 to –74) occurred in infants younger than 3 months,
although the incidence remained highest in this age group. Infants younger than 3 months were also the only age
group in which there were fewer cases in 2013 than in 2011 (118 cases in 2011 vs 72 cases in 2013), before the
resurgence. 26 684 women included in the Clinical Practice Research Datalink had a livebirth between
Oct 1, 2012 and Sept 3, 2013; the average vaccine coverage before delivery based on this cohort was 64%. Vaccine
eff ectiveness based on 82 confi rmed cases in infants born from Oct 1, 2012, and younger than 3 months at onset was
91% (95% CI 84 to 95). Vaccine eff ectiveness was 90% (95% CI 82 to 95) when the analysis was restricted to cases in
children younger than 2 months.

Interpretation Our assessment of the programme of pertussis vaccination in pregnancy in England is consistent with
high vaccine eff ectiveness. This eff ectiveness probably results from protection of infants by both passive antibodies
and reduced maternal exposure, and will provide valuable information to international policy makers.